Portland, OR -- (SBWire) -- 06/22/2017 --Inflammation is the mechanism of innate immunity, which eliminates the cause of injury. Sometimes, the body's defense system inappropriately triggers inflammation against its own cells, resulting in inflammatory autoimmune diseases. Reducing inflammation is one of the primary therapeutic strategies in acute as well as chronic diseases such as arthritis, psoriasis, and asthma. The rising incidences of autoimmune and respiratory conditions, extensive drug development pipeline, and increasing popularity of anti-inflammatory drugs with lesser side effects are the key factors driving the growth of the global anti-inflammatory therapeutics market. In addition, growing awareness about anti-inflammatory therapeutics and government initiatives, in the Asia pacific and LAMEA would further boost the market growth. However, adverse effects associated with long term consumption of drugs, namely NSAIDs and Corticosteroids would limit the market growth to a certain extent.
"Early Buyers Will Receive 20% Customization on This Report."
The anti-inflammatory biologic segment held 3/5th of overall market in 2014. The Asia Pacific market would exhibit the highest CAGR of 8.5% during the forecast period.
Key findings of Anti-inflammatory Therapeutics Market:
1. Arthritis indication was the major revenue generating segment in the global anti-inflammatory therapeutics market in 2014 followed by respiratory diseases
2. Psoriasis segment is the projected to grow at a CAGR of 8.1%, fastest among all
3. North America would continue to lead the market through 2020, currently accounts for about half of the global revenue
4. The U.S. accounted for about 5/6thof the North America anti-inflammatory therapeutics market revenue in 2014
5. Asia-Pacific is projected to be the fastest growing market
Get PDF brochure of the report at: https://www.alliedmarketresearch.com/request-sample/286
In developed economies, such as North America and Europe, branded drugs are preferred over generics whereas there has been a reverse trend in developing economies. This is evident from the fact that about 50% of the anti-inflammatory biologics market has its presence in the North America, whereas, Asia Pacific and LAMEA collectively accounted for 35% share in NSAIDs market as compared to about just 25% share of the branded biologics market in 2014.
Companies are adopting drug pipeline development and product launch as key strategies to overcome patent expiries of existing drugs and gain additional market share. Key companies profiled in the report are Pfizer Inc., Abbvie Inc., Johnson & Johnson, GlaxoSmithKline, Merck & CO., Inc. Novartis, F. Hoffman La Roche AG, Eli Lily and Company, AstraZeneca PLC. and Amgen.
